Alzheimer’s player Anavex reveals SEC probe; shares dive

John Carroll

of took a nasty hit after the New York-based biotech issued a 10-K this morning that included news of an SEC , evidently focused on "unusual" market activity for their stock.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS